journal article·2021-10

Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole‐Cell Components of Tumor Tissues or Cells

Lin Ma, Lu Diao, Zuofu Peng, Yun Jia, Huimin Xie, Baisong Li, Jianting Ma, Meng Zhang, Lifang Cheng, Dawei Ding, Xuenong Zhang, Huabing Chen, Fengfeng Mo, Honglv Jiang, Guoqiang Xu, Fenghua Meng, Zhiyuan Zhong, Mi Liu

Advanced Materials· Volume 33· Issue 43
Publisher page

Abstract

Abstract Tumor tissues/cells are the best sources of antigens to prepare cancer vaccines. However, due to the difficulty of solubilization and delivery of water‐insoluble antigens in tumor tissues/cells, including water‐insoluble antigens into cancer vaccines and delivering such vaccines efficiently to antigen‐presenting cells (APCs) remain challenging. To solve these problems, herein, water‐insoluble components of tumor tissues/cells are solubilized by 8 m urea and thus whole components of micrometer‐sized tumor cells are reasssembled into nanosized nanovaccines. To induce maximized immunization efficacy, various antigens are loaded both inside and on the surface of nanovaccines. By encapsulating both water‐insoluble and water‐soluble components of tumor tissues/cells into nanovaccines, the nanovaccines are efficiently phagocytosed by APCs and showed better therapeutic efficacy than the nanovaccine loaded with only water‐soluble components in melanoma and breast cancer. Anti‐PD‐1 antibody and metformin can improve the efficacy of nanovaccines. In addition, the nanovaccines can prevent lung cancer (100%) and melanoma (70%) efficiently in mice. T cell analysis and tumor microenvironment analysis indicate that tumor‐specific T cells are induced by nanovaccines and both adaptive and innate immune responses against cancer cells are activated by nanovaccines. Overall, this study demonstrates a universal method to make tumor‐cell‐based nanovaccines for cancer immunotherapy and prevention.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Nanoplatforms for cancer theranostics · Phagocytosis and Immune Regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics College of Pharmaceutical Sciences Soochow University Suzhou 215123 P. R. China

Alpha X (Beijing) Biotech Co., Ltd. Beijing 102600 P. R. China

Department of Naval Nutrition and Food Hygiene Faculty of Naval Medicine Naval Medical University Shanghai 200433 P. R. China

Biomedical Polymers Laboratory College of Chemistry Chemical Engineering and Materials Science Soochow University Suzhou 215123 P. R. China

Funding

Soochow University

References (40)

Show source-provided references
1. 10.1038/nrc.2016.1610.1038/nrc.2016.16 ↗
2. 10.1038/nri.2017.13110.1038/nri.2017.131 ↗
3. 10.1038/s41467-018-03915-410.1038/s41467-018-03915-4 ↗
4. 10.1021/acs.nanolett.0c0114010.1021/acs.nanolett.0c01140 ↗
5. 10.1038/nri.2017.14010.1038/nri.2017.140 ↗
6. 10.1016/j.biomaterials.2021.12070910.1016/j.biomaterials.2021.120709 ↗
7. 10.1172/JCI8000910.1172/JCI80009 ↗
8. 10.1038/nature2299110.1038/nature22991 ↗
9. 10.1038/nature2300310.1038/nature23003 ↗
10. 10.1023/A:102045253182810.1023/A:1020452531828 ↗
11. 10.1016/j.ijpharm.2005.03.03510.1016/j.ijpharm.2005.03.035 ↗
12. 10.1038/nnano.2017.11310.1038/nnano.2017.113 ↗
13. 10.1126/science.aaa497110.1126/science.aaa4971 ↗
14. 10.1007/s00204-015-1458-010.1007/s00204-015-1458-0 ↗
15. 10.1038/nnano.2013.18110.1038/nnano.2013.181 ↗
16. 10.1038/nmat244210.1038/nmat2442 ↗
17. 10.1073/pnas.060858210410.1073/pnas.0608582104 ↗
18. 10.1038/s41565-019-0512-010.1038/s41565-019-0512-0 ↗
19. 10.1038/nature1442610.1038/nature14426 ↗
20. 10.1172/jci.insight.8590210.1172/jci.insight.85902 ↗
21. 10.1172/JCI8000810.1172/JCI80008 ↗
22. 10.1158/0008-5472.CAN-11-372210.1158/0008-5472.CAN-11-3722 ↗
23. 10.1038/nri325410.1038/nri3254 ↗
24. 10.3389/fimmu.2018.0287410.3389/fimmu.2018.02874 ↗
25. 10.1038/s41586-019-1671-810.1038/s41586-019-1671-8 ↗
26. 10.1126/science.125110210.1126/science.1251102 ↗
27. 10.1038/s41571-018-0001-710.1038/s41571-018-0001-7 ↗
28. 10.1038/nrclinonc.2016.6610.1038/nrclinonc.2016.66 ↗
29. 10.1006/clim.1999.482010.1006/clim.1999.4820 ↗
30. 10.3389/fmicb.2018.0133610.3389/fmicb.2018.01336 ↗
31. 10.1073/pnas.141763611210.1073/pnas.1417636112 ↗
32. 10.1016/j.molcel.2018.07.03010.1016/j.molcel.2018.07.030 ↗
33. 10.1007/978-1-4939-6759-9_1710.1007/978-1-4939-6759-9_17 ↗
34. 10.1038/s41586-019-1922-810.1038/s41586-019-1922-8 ↗
35. 10.1038/s41586-019-1914-810.1038/s41586-019-1914-8 ↗
36. 10.1038/s41586-019-1906-810.1038/s41586-019-1906-8 ↗
37. 10.1038/s41586-020-2056-810.1038/s41586-020-2056-8 ↗
38. 10.1021/acs.jproteome.7b0084310.1021/acs.jproteome.7b00843 ↗
39. 10.1126/scitranslmed.aal492210.1126/scitranslmed.aal4922 ↗
40. 10.1080/2162402X.2019.165909310.1080/2162402X.2019.1659093 ↗